228742 - Kidney Cancer: Drugs (Answered)

Keith Vaz
To ask the Secretary of State for Health, what the Cancer Drugs Fund's policy is on funding Sunitib for the treatment of kidney cancer; and what the reasons are for any exclusions in the Cancer Drugs Fund's policy towards treatment of this form of cancer.

George Freeman

The National Institute for Health and Care Excellence (NICE) has recommended sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma subject to certain criteria. NICE does not recommend sunitinib for the second-line treatment of this condition.

Sunitinib for the treatment of kidney cancer is not included on the national list of drugs provided routinely through the Cancer Drugs Fund and clinicians are able to apply for individual patients to receive the drug on an exceptional basis.